John Ferbas
Overview
Explore the profile of John Ferbas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu J, Lee J, Yuan E, Wakefield D, Kanke M, Pruitt D, et al.
Mol Ther Nucleic Acids
. 2024 Oct;
35(4):102335.
PMID: 39380712
Small interfering RNAs (siRNAs) hold considerable therapeutic potential to selectively silence previously "undruggable" disease-associated targets, offering new opportunities to fight human diseases. This therapeutic strategy, however, is limited by the...
2.
Sherman D, Liu L, Mamrosh J, Xie J, Ferbas J, Lomenick B, et al.
Proc Natl Acad Sci U S A
. 2024 Apr;
121(18):e2318619121.
PMID: 38657050
Nonalcoholic fatty liver disease, recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is a progressive metabolic disorder that begins with aberrant triglyceride accumulation in the liver and can lead to...
3.
Sherman D, Liu L, Mamrosh J, Xie J, Ferbas J, Lomenick B, et al.
bioRxiv
. 2023 Oct;
PMID: 37873239
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is a progressive metabolic disorder that begins with aberrant triglyceride accumulation in the liver and can lead...
4.
Tokuda J, Xie J, Jawa V, Hawkins J, Ferbas J, Joh N, et al.
J Pharm Sci
. 2022 Feb;
111(4):1012-1023.
PMID: 35139332
Subcutaneous (SubQ) injection is a common administration route for biotherapeutics. However, limited tools are available for understanding the dynamic relationships between drug products and resident cells following injection. Advances in...
5.
McBride H, Jassem S, Chow V, Kanakaraj P, Lebrec H, Kuhns S, et al.
Biologicals
. 2021 Jul;
72:42-53.
PMID: 34303595
ABP 798 is a biosimilar to Rituxan® (rituximab reference product [RP]). Non-clinical assessments relevant to the primary and secondary mechanisms of action (MOA) contribute to the totality of the evidence...
6.
Jassem S, Wang W, Sweet H, Manoukian R, Chow V, Kanakaraj P, et al.
Pharm Res
. 2019 Nov;
36(12):177.
PMID: 31696314
Purpose: The in vitro and in vivo pharmacologic assessment of ABP 980 similarity to its reference product is intended to compare the activity of ABP 980 and trastuzumab and support...
7.
Kinderman F, Yerby B, Jawa V, Joubert M, Joh N, Malella J, et al.
J Pharm Sci
. 2019 Jan;
108(6):1953-1963.
PMID: 30684540
Antibody therapeutics with poor solubility in the subcutaneous matrix may carry unintended risks when administered to patients. The objective of this work was to estimate the risk of antibodies that...
8.
Stewart J, Green C, Jones N, Liang M, Xu Y, Wilkins D, et al.
Cytometry B Clin Cytom
. 2015 Dec;
90(2):110-6.
PMID: 26704557
The measurement of the binding of a biotherapeutic to its cellular target, receptor occupancy (RO), is increasingly important in development of biologically-based therapeutic agents. Receptor occupancy (RO) assays by flow...
9.
Recommendations for the development and validation of flow cytometry-based receptor occupancy assays
Green C, Stewart J, Hogerkorp C, Lackey A, Jones N, Liang M, et al.
Cytometry B Clin Cytom
. 2015 Nov;
90(2):141-9.
PMID: 26566147
Receptor occupancy measurements demonstrate the binding of a biotherapeutic agent to its extra-cellular target and represent an integral component of the pharmacodynamic (PD) portfolio utilized to advance the development and...
10.
Stohl W, Merrill J, Looney R, Buyon J, Wallace D, Weisman M, et al.
Arthritis Res Ther
. 2015 Aug;
17:215.
PMID: 26290435
Introduction: Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies was to characterize the safety,...